期刊文献+

狼疮性肾炎不同免疫抑制治疗方案疗效分析 被引量:3

Different immunosuppressive strategies in the treatment of lupus nephritis
原文传递
导出
摘要 目的比较不同免疫抑制治疗方案治疗狼疮性肾炎(lupus nephritis,LN)的疗效,为今后优化LN的治疗提供参考及依据。方法收集2008年6月至2011年9月广东医学院附属医院肾内科经肾活检诊断为Ⅳ型、Ⅴ型、Ⅴ+Ⅲ型以及Ⅴ+Ⅳ型LN且门诊随诊不低于6个月的患者95例,记录所有患者住院和随诊期间临床及实验室检查结果以及免疫抑制药物使用情况,进行疗效分析。结果不同病理类型LN的诱导缓解率差异无统计学意义,各治疗方案总缓解率可达85%左右。诱导治疗方案以糖皮质激素(P)+环磷酰胺(CTX)为"基本方案",达完全缓解CTX累积用量约2.5 g;达到完全缓解时间约13周;在P+CTX组合治疗基础上加用羟氯喹(HCQ)或雷公藤(TW)未能提高诱导缓解率。维持治疗方案中P+硫唑嘌呤(Aza)的持续缓解时间为83.7周,明显长于其他治疗方案。结论 "个体化"免疫抑制治疗方案对LN的治疗效果满意;在维持治疗方面,P+Aza有更长的持续缓解时间。 Objective To analyze the different immunosuppressive strategies in the treatment of lupus nephritis (LN) and provide evidences for the choices of therapeutic regimen. Methods A total of 95 patients with lupus nephritis of Class IV, Class V , Class III + V , and Class IV + V were included, and followed up for at least 6 months in Institute of Nephrology, the Affiliated Hospital of Guangdong Medical College from Jun. 2008 to Sep. 2011. Clinical parameters, laboratory data and the use of immunosuppressive drugs during the hospitalization and follow-up period were recorded and analyzed retrospectively. Results There was no significant difference in the remission rates among different pathological types. The total remission rate of this individualized regimen was up to more than 85%. Prednison (P) plus cyclophosphamide (CTX) was the "basic strategy" and the cumulative amount of CTX was about 2. 5 g when complete remission was achieved. And the complete remission time was about 13 weeks. Addition of hydroxychloroquine (HCQ) or tripterygium glycosides (TW) to the combination of P and CTX did not enhance the initial remission rate. Among different maintenance treatment programs, the longest sustained remission was obtained by P plus azathioprinc (Aza). Conclusion Our individualized immunosuppressive regimen shows satisfactory outcomes in LN patients. The strategy of P plus Aza seems to have a longer sustained remission.
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2013年第12期943-947,共5页 Chinese Journal of Practical Internal Medicine
基金 国家自然科学基金(81202346)
关键词 狼疮性肾炎 糖皮质激素 环磷酰胺 羟氯喹 雷公藤 Lupus nephritis glucocorticoid cyclophosphamide hydroxychloroquine tripterygium glycosides
  • 相关文献

参考文献14

  • 1Weening JJ,D,Agati vd, Schwartz MM, et al. The classification ofglomerulonephritis in systemic lupus erythematosus revisited [ J]. JAm Soc Nephrol,2004,15(2) :241 -250.
  • 2康莉,夏天.狼疮性肾炎的诊疗新进展[J].医学综述,2010,16(15):2310-2313. 被引量:10
  • 3付平,秦伟.KDIGO指南解读:狼疮性肾炎治疗[J].中国实用内科杂志,2012,32(12):921-924. 被引量:11
  • 4Hochberg MC, Updating the American College of Rheumatology re-vised criteria for the classification of systemic lupus erythematosus[Letter] [ J]. Arthritis Rheum, 1997 ,40(9) :1725.
  • 5Kidney Disease : Improving Global Outcomes ( KDIGO) Glomerulo-nephritis Work Group. KDIGO Clinical Practice Guideline for Glo-merulonephritis [J]. Kidney int Suppl. ,2012,2(2) : 139 -274.
  • 6Sis6 A,Ramos-Casals M,Bov6 A,et al. Previous antimalarial therapyin patients diagnosed with lupus nephritis : influence on outcomesand survival [ J]. Lupus,2008 ,17(4) :281 -288.
  • 7Pons-Estel GJ,Alarc6n GS, McGwin G Jr,et al. Protective effect ofhydroxychloroquine on renal damage in patients with lupus nephri-tis :LXV,data from a multiethnic US cohort [ J]. Arthritis Rheum,2009,61(6):830 -839.
  • 8刘志红,黎磊石.狼疮肾炎的治疗[J].中国实用内科杂志:临床前沿版,2006,26(1):86-87. 被引量:13
  • 9Kim YG, Kim HW, Cho YM, et al. The dlifferenee between lupusnephritis class IV-G and IV-S in Koreans : focus on the response tocyclophosphamide induction treatment [ J]. Rheumatology ( Ox-ford) ,2008,47(3) :311 -314.
  • 10Hiramatsu N,Kumiwa T,lkeuehi H,et al. Revised classification oflupus nephritis is valuable in predicting renal outcome with an in-dication of the proportion of glomemli affected by chronic lesions[J]. Rheumatology (Oxford) ,2008,47(5) :702 -707.

二级参考文献49

  • 1刘志红,黎磊石.狼疮肾炎的治疗[J].中国实用内科杂志:临床前沿版,2006,26(1):86-87. 被引量:13
  • 2Mumtaz P,Alexandra MC,Ian NB,et al.The prevalence and incidence of biopsy proven lupus nephrtitis in the UK[J].Arthritis Rheum,2006,54(9):2963-2969.
  • 3Cervera R,Khamashta M,Font J,et al.Morbidity and mortality in systemic lupus erythematosus during a 10-year period:a comparison of early and late manifestations in a cohort of 1000 patients[J].Medicine(Baltimore),2003,82(5):299-308.
  • 4Hochberg MC.Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus[J].Arthritis Rheum,1997,40(9):1725.
  • 5Wallace DJ.What's new in the management of lupus since 2000[J].J Clin Rheumatol,2006,12(6):307-313.
  • 6Brenner and Rector.The kidney[M].8 th ed.Publisher:W.B.Saunders Company,2007:1067.
  • 7Weening JJ,D'Agati VD,Schwartz MM,et al.The classification of glomerulonephritis in systemic lupus erythe matousus revisited[J].Kidney Int,2004,65(2):521-530.
  • 8Korbet SM,Lewis EJ,Schwartz MM,et al.Factors predictive of outcome in severe lupus nephritis[J].Am J Kidney Dis,2000,35(5):904-914.
  • 9Stratta P,Mesiano P,Campo A,et al.Life expectancy of women with lupus nephritis now approaches that of the general population[J].Int J Immunopathol Pharmacol.2009,22(4):1135-1141.
  • 10Austin HA.Therapy of lupusnephritis,controlled trial of prednisone and cytotoxic drugs[J].N Engl J Med,1986,314(10):614-619.

共引文献33

同被引文献39

引证文献3

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部